{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:16:14Z","timestamp":1776482174825,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.05.041","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T17:21:40Z","timestamp":1558372900000},"page":"3856-3865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017\u20132018 season"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-1502","authenticated-orcid":false,"given":"Silvia","family":"Perez-Vilar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Chi","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Lufkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"MaCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Kelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.041_b0005","unstructured":"U.S. Food and Drug Administration, Vaccines licensed for use in the United States; 2018."},{"key":"10.1016\/j.vaccine.2019.05.041_b0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.05.041_b0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2019.05.041_b0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1473-3099(10)70140-7","article-title":"Guillain-Barre syndrome after exposure to influenza virus","volume":"10","author":"Lehmann","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.041_b0025","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"397","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.05.041_b0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.041_b0035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/014107687907200908","article-title":"Guillain-Barre syndrome: the swine influenza virus vaccine incident in the United States of America, 1976\u201377: preliminary communication","volume":"72","author":"Langmuir","year":"1979","journal-title":"J R Soc Med"},{"key":"10.1016\/j.vaccine.2019.05.041_b0040","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/oxfordjournals.aje.a113809","article-title":"An epidemiologic and clinical evaluation of Guillain-Barr\u00e9 syndrome reported in association with the administration of swine influenza vaccines","volume":"119","author":"Langmuir","year":"1984","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the national influenza immunization program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0050","doi-asserted-by":"crossref","unstructured":"Arya D, Said M, Izurieta HS, Perez-Vilar S, Zinderman C, Wernecke M, et al. Surveillance for Guillain-Barr\u00e9 syndrome after 2015\u20132016 and 2016\u20132017 influenza vaccination of medicare beneficiaries, Submitted to Vaccine (2019).","DOI":"10.1016\/j.vaccine.2019.08.045"},{"key":"10.1016\/j.vaccine.2019.05.041_b0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.041_b0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amepre.2010.05.022","article-title":"Evaluation of Guillain-Barre Syndrome among recipients of influenza vaccine in 2000 and 2001","volume":"39","author":"Burwen","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2019.05.041_b0065","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198106253042601","article-title":"Guillain-Barr\u00e9 syndrome and the 1978\u20131979 influenza vaccine","volume":"304","author":"Hurwitz","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.041_b0070","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","article-title":"Guillain-Barr\u00e9 syndrome after influenza vaccination in adults: a population-based study","volume":"166","author":"Juurlink","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2019.05.041_b0075","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1982.03330060038030","article-title":"Guillain-Barr\u00e9 syndrome in the United States, 1979\u20131980 and 1980\u20131981: lack of an association with influenza vaccination","volume":"248","author":"Kaplan","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.05.041_b0080","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barr\u00e9 syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.041_b0085","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/oxfordjournals.aje.a115974","article-title":"Guillain-Barr\u00e9 syndrome and influenza vaccination in the US Army, 1980\u20131988","volume":"133","author":"Roscelli","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0090","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.05.041_b0095","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.041_b0100","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2105\/AJPH.2011.300510","article-title":"Surveillance for Guillain-Barr\u00e9 Syndrome After Influenza Vaccination Among the Medicare Population, 2009\u20132010","volume":"102","author":"Burwen","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2019.05.041_b0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/aje\/kwt051","article-title":"Chart-confirmed Guillain-Barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009\u20132010","volume":"178","author":"Polakowski","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.vaccine.2019.05.041_b0110","first-page":"e82222","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"2014","author":"Romio","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.05.041_b0115","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.vaccine.2017.03.087","article-title":"Near real-time surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2010\/11 to 2013\/14","volume":"35","author":"Sandhu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.041_b0120","series-title":"ASA biopharmaceutical section statistics workshop: statistical issues and challenges in post-licensure safety surveillance and treatment effect assessment","article-title":"Updating sequential probability ratio test for real-time surveillance of vaccine\/drug safety","author":"MaCurdy","year":"2012"},{"key":"10.1016\/j.vaccine.2019.05.041_b0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/sam.11234","article-title":"Robustness properties of a sequential test for vaccine safety in the presence of misspecification","volume":"7","author":"Franks","year":"2014","journal-title":"Stat Anal Data Min ASA Data Sci J"},{"key":"10.1016\/j.vaccine.2019.05.041_b0130","unstructured":"Forshee RA, Hu M, Arya D, Perez-Vilar S, Anderson SA, Lo A, et al. A simulation study of the statistical power and signaling characteristics of an early season sequential test for influenza vaccine safety, Pharmacoepidemiol Drug Saf (forthcoming)."},{"key":"10.1016\/j.vaccine.2019.05.041_b0135","unstructured":"Centers for Disease Control and Prevention. June 2018 Advisory Committee on Immunization Practices (ACIP). End-of-season update: 2017\u20132018 influenza vaccine safety monitoring; 2018."},{"key":"10.1016\/j.vaccine.2019.05.041_b0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.041_b0145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/infdis\/jiw641","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012\u20132013 and 2013\u20132014","volume":"215","author":"Shay","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.041_b0150","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.041_b0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/01621459.1986.10478280","article-title":"Multiple imputation for interval estimation from simple random samples with ignorable nonresponse","volume":"81","author":"Rubin","year":"1986","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.vaccine.2019.05.041_b0160","unstructured":"Centers for Disease Control and Prevention. National, regional, and state level outpatient illness and viral surveillance; 2018."},{"key":"10.1016\/j.vaccine.2019.05.041_b0165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"10.1016\/j.vaccine.2019.05.041_b0170","unstructured":"U.S. Food and Drug Administration. November 24, 2015 Approval letter - FLUAD 2015."},{"key":"10.1016\/j.vaccine.2019.05.041_b0175","unstructured":"Seqirus I. Fluad [package insert]. Summit, NJ; 2018."},{"issue":"11","key":"10.1016\/j.vaccine.2019.05.041_b0180","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.vaccine.2019.01.052","article-title":"Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016\u2013June 2018","volume":"37","author":"Haber","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.041_b0185","doi-asserted-by":"crossref","first-page":"e82222","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.05.041_b0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.05.041_b0195","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0200","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-Barre syndrome during the 2009\u20132010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0205","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/aje\/kws197","article-title":"Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009\u20132010","volume":"175","author":"Yih","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0210","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.3220","article-title":"The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009\u20132010 seasonal influenza vaccines: results from self-controlled analyses","volume":"21","author":"Tokars","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.05.041_b0215","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm","volume":"343","author":"Bardage","year":"2011","journal-title":"Sweden BMJ"},{"key":"10.1016\/j.vaccine.2019.05.041_b0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vaccine.2011.10.062","article-title":"Antibody persistence and response to 2010\u20132011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children","volume":"30","author":"Gilca","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.041_b0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.05.041_b0230","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pone.0000344","article-title":"Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database","volume":"2","author":"Tam","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.05.041_b0235","unstructured":"Hu M, Perez-Vilar S, Wernecke M, Arya D, Kelman J, Chu S, et al. Early season self-controlled risk interval analyses of Guillain-Barr\u00e9 syndrome risk following influenza vaccination using claims delay adjustment [abstract], 35th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) (2019)."},{"key":"10.1016\/j.vaccine.2019.05.041_b0240","doi-asserted-by":"crossref","first-page":"e67185","DOI":"10.1371\/journal.pone.0067185","article-title":"Guillain-Barr\u00e9 syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009\u20132011","volume":"8","author":"Greene","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.05.041_b0245","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amepre.2014.10.016","article-title":"Medicare claims versus beneficiary self-report for influenza vaccination surveillance","volume":"48","author":"Lochner","year":"2015","journal-title":"Am J Prev Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:13Z","timestamp":1759401193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19306656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":49,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19306656"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017\u20132018 season","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}